Motif Neurotech
Motif Neurotech is a clinical-stage medical device company developing the DOT implant, a minimally invasive, battery-free brain stimulator that uses magnetoelectric wireless power to treat treatment-resistant depression in patients who have failed multiple antidepressants.
- Company typePrivate
- Founded2022
- HeadquartersHouston, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Motif Neurotech does
Motif Neurotech is a clinical-stage medical device company developing minimally invasive, battery-free bioelectronic implants for the monitoring and treatment of severe mental illness, with an initial focus on treatment-resistant depression (TRD) in adults who have failed two or more antidepressant medications. The company's lead product is the DOT / DOT XCS System, a pea- to blueberry-sized implant placed in the skull bone above the dura that never contacts brain tissue and is implanted in a roughly 20-30 minute outpatient procedure. DOT wirelessly stimulates the Central Executive Network (CEN) using patent-pending magnetoelectric wireless power transfer technology originally developed at Rice University's Robinson Lab, and is paired with an external wearable hat that delivers prescribed stimulation sessions of about 30 minutes at home. A recently announced multi-year commercial supply agreement with MintNeuro adds specialized miniaturized neural-interface chips to the platform across pre-clinical, early clinical, and pivotal-trial phases.
Motif received FDA Breakthrough Device Designation for its XCS implant and, in April 2026, became the fastest implantable BCI company to advance from founding to FDA Investigational Device Exemption (IDE) approval, achieved in just four years. The company is currently running the RESONATE Early Feasibility Study across up to eight U.S. medical institutions including Baylor College of Medicine, Massachusetts General Brigham, and Emory Healthcare, enrolling approximately 10 participants and tracking safety over 12 months. It holds granted patents in the United States, Europe, and Japan covering the DOT device. Leadership combines academic neuroscience (CEO Jacob Robinson, PhD, with 60+ peer-reviewed publications and $40M+ federal funding from Rice) with industry neuromodulation depth (CTO Steve Goetz, Bakken Fellow with 160+ patents from 26 years at Medtronic) and practicing neurosurgery founders (Sameer Sheth, Sunil Sheth).
The company is pre-revenue and sells no commercial product today; its only cash inflows are equity financings and non-dilutive grants. As of December 2025 Motif had raised over $30M in cumulative venture capital, anchored by an $18.75M Series A closed in January 2024 with a syndicate led by Arboretum Ventures and including Satori Capital, Capital Factory, Divergent Capital, Dolby Family Ventures, Empath Ventures, KdT Ventures, PsyMed Ventures, re.Mind Capital, and TMC Innovation. Non-dilutive capital includes a £5.8M UK ARIA grant (January 2025) and selection into the ARPA-H EVIDENT federal initiative (April 2026), a program that may allocate up to $139.4M to mental health therapies. Future commercialization is expected to flow through leading U.S. academic medical centers and specialty neurology and psychiatry practices via a direct sales motion, with device pricing to be set after FDA marketing authorization.
Motif Neurotech firmographics
Firmographics- Name
- Motif Neurotech
- Legal name
- Motif Neurotech, Inc.
- Website
- https://motifneuro.tech
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Motif Neurotech is a clinical-stage medical device company developing the DOT implant, a minimally invasive, battery-free brain stimulator that uses magnetoelectric wireless power to treat treatment-resistant depression in patients who have failed multiple antidepressants.
- Ownership category
- akta.pro rank
Motif Neurotech industry classification
Industry- Product category
- Implantable Neuromodulation Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK)
- akta.pro secondary industry
- Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)
Keywords
Where Motif Neurotech is headquartered
LocationHeadquarters
- HQ city
- Houston
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Motif Neurotech business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Pre-revenue (clinical-stage): Motif Neurotech is pre-revenue: the company is conducting its first-in-human RESONATE Early Feasibility Study (IDE approved April 27, 2026) for the DOT device in treatment-resistant depression. Future commercialization will rely on selling or implanting the DOT/DOT XCS System into healthcare systems.
- Non-dilutive Grant Funding: Receives non-dilutive funding from government grant programs (UK ARIA awards of $5.8M; £4.7M UK ARIA-funded Brain Mesh project; ARPA-H EVIDENT initiative participation up to $139.4M in federal funding). These are funding sources, not commercial revenue.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Not publicly disclosed (pre-commercial clinical-stage product) |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels8 records
Motif Neurotech product offering
Product offeringCore offering
Motif Neurotech develops a minimally invasive, wirelessly powered implantable brain stimulator called DOT (Digitally programmable Over-brain Therapeutic), also referenced as the DOT XCS System. The pea-sized, battery-free device is implanted in the skull bone above the dura in a ~20–30 minute outpatient procedure and pairs with a wearable hat controller to deliver targeted stimulation of the Central Executive Network (CEN) for the treatment of treatment-resistant depression. The company is clinical-stage, having received FDA Investigational Device Exemption (IDE) approval in April 2026 for its RESONATE Early Feasibility Study.
Product overview
Motif Neurotech offers a single integrated therapeutic brain-computer interface (BCI) platform anchored by its DOT (Digitally programmable Over-brain Therapeutic) implantable brain stimulator — also referenced as the DOT XCS System — which is paired with a wearable wireless hat controller that delivers at-home outpatient treatment for treatment-resistant depression. The DOT implant and its companion hat transmitter together form the core product architecture, while the Patient Registry serves as the company's clinical-trial engagement service, capturing interest from patients, caregivers, and providers for upcoming RESONATE Early Feasibility Study enrollment.
Differentiator
Problem solved
Functional benefit
Brands
- DOT: DOT (Digitally programmable Over-brain Therapeutic) — Motif's miniature, wirelessly powered, skull-implanted brain-computer interface designed to stimulate the Central Executive Network for treatment-resistant depression. Described as blueberry- or pea-sized.
- DOT XCS System
Products and services
- DOT (Digitally programmable Over-brain Therapeutic) / DOT XCS System Cosmetically invisible, blueberry- to pea-sized, battery-free implantable brain stimulator placed in the skull bone that wirelessly stimulates the Central Executive Network via magnetoelectric power transfer to treat treatment-resistant depression from home. Implanted in a ~20–30 minute outpatient procedure that does not expose or contact the brain.
- Wireless Wearable Hat Controller (paired transmitter) A wearable cap-style transmitter that pairs with the DOT implant to wirelessly deliver power and prescribed stimulation sessions, enabling at-home treatment for treatment-resistant depression without repeated clinic visits.
- Patient Registry Web-based registry that invites individuals with treatment-resistant depression, caregivers, and providers to register interest in upcoming Motif Neurotech clinical trial opportunities and related research.
Quantifiable outcome
- FDA IDE approval achieved in just 4 years from founding (fastest implantable BCI company to reach IDE with a novel device)
- +4 more outcomes
Companies that use Motif Neurotech
Customer profileIdeal customer profiles3 records
Motif Neurotech technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
Feature7 records
Motif Neurotech partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered flagship and core.
- MintNeuroflagshipStrategic partnership combining MintNeuro's miniaturised neural interface chip technology with Motif's clinical-stage therapeutic BCI implant platform for mental health conditions. Includes a multi-year commercial supply agreement spanning pre-clinical, early clinical, and pivotal trial phases. Builds on over a year of joint development, with Motif's sensing chip already integrated into devices used in pre-clinical work. Motif has established a U.K. subsidiary to collaborate with MintNeuro on software and data science tied to the ARIA-funded Brain Mesh project.
- Baylor College of MedicinecoreClinical trial site for the RESONATE Early Feasibility Study of Motif's DOT device in treatment-resistant depression. Listed among up to eight leading U.S. medical institutions hosting the trial.
- Massachusetts General BrighamcoreClinical trial site for the RESONATE Early Feasibility Study of Motif's DOT device in treatment-resistant depression. Listed among up to eight leading U.S. medical institutions hosting the trial.
- Emory HealthcarecoreClinical trial site for the RESONATE Early Feasibility Study of Motif's DOT device in treatment-resistant depression. Listed among up to eight leading U.S. medical institutions hosting the trial.
- ARPA-H (U.S. HHS) — EVIDENT initiativeflagshipMotif Neurotech joined the ARPA-H EVIDENT initiative, which will collectively fund up to $139.4M to develop new effective therapies for behavioral health conditions including depression, anxiety, addiction, and PTSD. The initiative allocates at least $50M to match state government investments in psychedelic research and aims to generate FDA-ready clinical endpoints for rapid-acting therapies such as neuromodulation.
- UK Government ARIA (Advanced Research and Invention Agency)flagshipMotif won UK government ARIA grants totaling $5.8M to develop its therapeutic brain-computer interface (announced January 20, 2025), aligned with the broader £4.7M Brain Mesh project. Provides non-dilutive funding and integration into ARIA's Precision Neurotechnologies programme.
- Rice University (Robinson Lab)flagshipRice University is the source of Motif's foundational magnetoelectric wireless power technology, developed over more than a decade by CEO Jacob Robinson's research group. Rice University News (April 28, 2026) explicitly covered 'Brain-computer interface based on Rice research wins FDA approval for first clinical trial'. Founders/advisors Kaiyuan Yang (Associate Professor of ECE, Rice) and Jacob Robinson retain Rice professorships while leading Motif.
- Texas Medical Center - Innovation (TMCi)coreMotif's brand-new lab and manufacturing home is located at Texas Medical Center - Innovation (TMCi), a start-up incubation hub in Houston providing access to cutting-edge resources and industry-leading mentorship.
Scale indicators10 records
Recent moves7 records
Expansion highlights6 records
Motif Neurotech competitors and assessment
Company assessmentDirect peers
- Blackrock Neurotech: Utah-based implantable brain-computer interface company developing neural recording/stimulation platforms for paralysis and other indications. Directly comparable as a peer implantable BCI company; COO Nick Halper previously led growth strategy and regulatory work at Blackrock before joining Motif.
- Neuralink: Elon Musk-founded implantable BCI company developing high-bandwidth cortical interfaces for paralysis and eventually other applications. Directly comparable as a peer implantable BCI; competes for the same press coverage, talent, and clinical site attention as Motif in the BCI race.
- Synchron: Stentrobot-derived endovascular BCI company targeting paralysis patients via a less-invasive, catheter-delivered electrode. Directly comparable as a peer BCI for clinical applications and as a competitor for patient/clinical-site mindshare in the implantable neurotech category.
- Precision Neuroscience: Neuralink co-founder-founded BCI company developing a thin-film cortical electrode array for high-resolution brain recording. Directly comparable as a peer implantable BCI startup competing for talent, capital, and clinical milestones in the cortical-interface space.
- Paradromics: Austin-based implantable BCI company building high-data-rate neural recording interfaces for medical and communication applications. Directly comparable as a peer implantable BCI startup; competes in the same clinical-stage BCI cohort as Motif.
Broad incumbents
- Medtronic: Global medical device leader with deep franchises in deep brain stimulation (Activa), spinal cord stimulation, and other neuromodulation therapies. Broad incumbent in the neuromodulation category; CTO Steve Goetz's 26-year Medtronic tenure and Bakken Fellowship make it the most directly relevant incumbent for talent/technology benchmarking, even though Medtronic's DBS targets movement disorders rather than TRD.
- Abbott: Major neuromodulation player with FDA-approved dorsal root ganglion and spinal cord stimulation systems (Proclaim, Eterna) and a deep DBS legacy via the legacy St. Jude portfolio. Broad incumbent in implantable neuromodulation; directly comparable on Class III implant manufacturing, regulatory, and commercial scale.
- Boston Scientific: Large-cap medical device incumbent with spinal cord stimulation, deep brain stimulation, and cardiac rhythm management franchises. Broad incumbent in implantable neuromodulation; Director of Manufacturing Jake Wiederin spent more than a decade at Boston Scientific supporting cardiac rhythm and neuromodulation portfolios.
- Saluda Medical: Clinical-stage neuromodulation company developing closed-loop spinal cord stimulation for chronic pain with Evoke/ECAP-controlled devices. Comparable as a peer implantable neuromodulation company with a sensing-enabled platform; multiple Motif engineers and staff previously worked at Saluda, making it a near-direct talent/technology comparator.
Emerging players
- BrainsWay: Commercial-stage company commercializing deep transcranial magnetic stimulation (Deep TMS) systems, including an FDA-cleared protocol for treatment-resistant depression. Comparable as a peer targeting TRD with a non-invasive neuromodulation modality that competes for the same patient population and clinical sites as Motif's eventual DOT offering.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights8 records
Customer concentration
Motif Neurotech social profiles
Digital presenceMotif Neurotech compliance and trust
Trust signalCompliance4 records
Motif Neurotech financial estimates
Financial estimateRevenue estimate
Valuation estimate
Motif Neurotech leadership team
Management profileNumber of profiles
Profiles19 records
Motif Neurotech subsidiaries and ownership
Company hierarchySubsidiaries1 record
Motif Neurotech funding detail
Funding detailFunding overview
Funding rounds3 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Motif Neurotech M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Motif Neurotech
What does Motif Neurotech do?
Motif Neurotech develops a minimally invasive, wirelessly powered implantable brain stimulator called DOT (Digitally programmable Over-brain Therapeutic), also referenced as the DOT XCS System. The pea-sized, battery-free device is implanted in the skull bone above the dura in a ~20–30 minute outpatient procedure and pairs with a wearable hat controller to deliver targeted stimulation of the Central Executive Network (CEN) for the treatment of treatment-resistant depression. The company is clinical-stage, having received FDA Investigational Device Exemption (IDE) approval in April 2026 for its RESONATE Early Feasibility Study.
Is Motif Neurotech a public or private company?
Motif Neurotech is a private company. It is classified as venture growth investor backed and is currently operating.
When was Motif Neurotech founded?
Motif Neurotech was founded in 2022. It employs 11 to 50 people.
Where is Motif Neurotech based?
Motif Neurotech is headquartered in Houston, United States, in the North America region.
How does Motif Neurotech make money?
Two revenue lines are on record. Pre-revenue (clinical-stage) is the primary driver. The others are non-dilutive Grant Funding.
Who are Motif Neurotech's main competitors?
Direct peers on record are Blackrock Neurotech, Neuralink, Synchron, Precision Neuroscience and Paradromics. Broad incumbents are Medtronic, Abbott, Boston Scientific and Saluda Medical. BrainsWay is listed as an emerging player.
Does Motif Neurotech have an API?
No public API is recorded for Motif Neurotech.
What industry is Motif Neurotech in?
Motif Neurotech's product category is Implantable Neuromodulation Devices. Its primary akta.pro industry code is HLAHAEAK, Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS), with a secondary code of HLAHACAE, Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables). Its NAICS code is 334510 and its SIC code is 3845.